198 related articles for article (PubMed ID: 31609054)
1. Site-Specific Encoding of Photoactivity in Antibodies Enables Light-Mediated Antibody-Antigen Binding on Live Cells.
Bridge T; Shaikh SA; Thomas P; Botta J; McCormick PJ; Sachdeva A
Angew Chem Int Ed Engl; 2019 Dec; 58(50):17986-17993. PubMed ID: 31609054
[TBL] [Abstract][Full Text] [Related]
2. Site-specific encoding of photoactivity and photoreactivity into antibody fragments.
Bridge T; Wegmann U; Crack JC; Orman K; Shaikh SA; Farndon W; Martins C; Saalbach G; Sachdeva A
Nat Chem Biol; 2023 Jun; 19(6):740-749. PubMed ID: 36797401
[TBL] [Abstract][Full Text] [Related]
3. Nanobody Targeting of Epidermal Growth Factor Receptor (EGFR) Ectodomain Variants Overcomes Resistance to Therapeutic EGFR Antibodies.
Tintelnot J; Baum N; Schultheiß C; Braig F; Trentmann M; Finter J; Fumey W; Bannas P; Fehse B; Riecken K; Schuetze K; Bokemeyer C; Rösner T; Valerius T; Peipp M; Koch-Nolte F; Binder M
Mol Cancer Ther; 2019 Apr; 18(4):823-833. PubMed ID: 30824613
[TBL] [Abstract][Full Text] [Related]
4. Engineering Homogeneous Photoactive Antibody Fragments.
Bridge T; Sachdeva A
Methods Mol Biol; 2023; 2676():21-40. PubMed ID: 37277622
[TBL] [Abstract][Full Text] [Related]
5. Affinity enhancement of nanobody binding to EGFR: in silico site-directed mutagenesis and molecular dynamics simulation approaches.
Farasat A; Rahbarizadeh F; Hosseinzadeh G; Sajjadi S; Kamali M; Keihan AH
J Biomol Struct Dyn; 2017 Jun; 35(8):1710-1728. PubMed ID: 27691399
[TBL] [Abstract][Full Text] [Related]
6. Identification and grafting of a unique peptide-binding site in the Fab framework of monoclonal antibodies.
Donaldson JM; Zer C; Avery KN; Bzymek KP; Horne DA; Williams JC
Proc Natl Acad Sci U S A; 2013 Oct; 110(43):17456-61. PubMed ID: 24101516
[TBL] [Abstract][Full Text] [Related]
7. Establishment of EMab-134, a Sensitive and Specific Anti-Epidermal Growth Factor Receptor Monoclonal Antibody for Detecting Squamous Cell Carcinoma Cells of the Oral Cavity.
Itai S; Yamada S; Kaneko MK; Chang YW; Harada H; Kato Y
Monoclon Antib Immunodiagn Immunother; 2017 Dec; 36(6):272-281. PubMed ID: 29090976
[TBL] [Abstract][Full Text] [Related]
8. Modulating antibody-dependent cellular cytotoxicity of epidermal growth factor receptor-specific heavy-chain antibodies through hinge engineering.
D'Eall C; Pon RA; Rossotti MA; Krahn N; Spearman M; Callaghan D; van Faassen H; Hussack G; Stetefeld J; Butler M; Durocher Y; Zhang J; Henry KA; Tanha J
Immunol Cell Biol; 2019 Jul; 97(6):526-537. PubMed ID: 30680791
[TBL] [Abstract][Full Text] [Related]
9. Epidermal growth factor receptor (EGFR) antibody down-regulates mutant receptors and inhibits tumors expressing EGFR mutations.
Perez-Torres M; Guix M; Gonzalez A; Arteaga CL
J Biol Chem; 2006 Dec; 281(52):40183-92. PubMed ID: 17082181
[TBL] [Abstract][Full Text] [Related]
10. Impact of intrinsic affinity on functional binding and biological activity of EGFR antibodies.
Zhou Y; Goenaga AL; Harms BD; Zou H; Lou J; Conrad F; Adams GP; Schoeberl B; Nielsen UB; Marks JD
Mol Cancer Ther; 2012 Jul; 11(7):1467-76. PubMed ID: 22564724
[TBL] [Abstract][Full Text] [Related]
11. Intraoperative fluorescence delineation of head and neck cancer with a fluorescent anti-epidermal growth factor receptor nanobody.
van Driel PB; van der Vorst JR; Verbeek FP; Oliveira S; Snoeks TJ; Keereweer S; Chan B; Boonstra MC; Frangioni JV; van Bergen en Henegouwen PM; Vahrmeijer AL; Lowik CW
Int J Cancer; 2014 Jun; 134(11):2663-73. PubMed ID: 24222574
[TBL] [Abstract][Full Text] [Related]
12. Identification of the epitope for the epidermal growth factor receptor-specific monoclonal antibody 806 reveals that it preferentially recognizes an untethered form of the receptor.
Johns TG; Adams TE; Cochran JR; Hall NE; Hoyne PA; Olsen MJ; Kim YS; Rothacker J; Nice EC; Walker F; Ritter G; Jungbluth AA; Old LJ; Ward CW; Burgess AW; Wittrup KD; Scott AM
J Biol Chem; 2004 Jul; 279(29):30375-84. PubMed ID: 15075331
[TBL] [Abstract][Full Text] [Related]
13. A novel glycoengineered bispecific antibody format for targeted inhibition of epidermal growth factor receptor (EGFR) and insulin-like growth factor receptor type I (IGF-1R) demonstrating unique molecular properties.
Schanzer JM; Wartha K; Croasdale R; Moser S; Künkele KP; Ries C; Scheuer W; Duerr H; Pompiati S; Pollman J; Stracke J; Lau W; Ries S; Brinkmann U; Klein C; Umana P
J Biol Chem; 2014 Jul; 289(27):18693-706. PubMed ID: 24841203
[TBL] [Abstract][Full Text] [Related]
14. A stable IgG-like bispecific antibody targeting the epidermal growth factor receptor and the type I insulin-like growth factor receptor demonstrates superior anti-tumor activity.
Dong J; Sereno A; Aivazian D; Langley E; Miller BR; Snyder WB; Chan E; Cantele M; Morena R; Joseph IB; Boccia A; Virata C; Gamez J; Yco G; Favis M; Wu X; Graff CP; Wang Q; Rohde E; Rennard R; Berquist L; Huang F; Zhang Y; Gao SX; Ho SN; Demarest SJ; Reff ME; Hariharan K; Glaser SM
MAbs; 2011; 3(3):273-88. PubMed ID: 21393993
[TBL] [Abstract][Full Text] [Related]
15. Immune response with long-term memory triggered by amorphous aggregates of misfolded anti-EGFR V
Golam Kibria M; Akazawa-Ogawa Y; Hagihara Y; Kuroda Y
Eur J Pharm Biopharm; 2021 Aug; 165():13-21. PubMed ID: 33971271
[TBL] [Abstract][Full Text] [Related]
16. The effect of pH dependence of antibody-antigen interactions on subcellular trafficking dynamics.
Devanaboyina SC; Lynch SM; Ober RJ; Ram S; Kim D; Puig-Canto A; Breen S; Kasturirangan S; Fowler S; Peng L; Zhong H; Jermutus L; Wu H; Webster C; Ward ES; Gao C
MAbs; 2013; 5(6):851-9. PubMed ID: 24492341
[TBL] [Abstract][Full Text] [Related]
17. Optimizing properties of antireceptor antibodies using kinetic computational models and experiments.
Harms BD; Kearns JD; Su SV; Kohli N; Nielsen UB; Schoeberl B
Methods Enzymol; 2012; 502():67-87. PubMed ID: 22208982
[TBL] [Abstract][Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
